

# Anders Wimo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7642603/publications.pdf>

Version: 2024-02-01

114  
papers

14,203  
citations

108046

37  
h-index

31191

106  
g-index

124  
all docs

124  
docs citations

124  
times ranked

18762  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dementia prevention: The potential long-term cost-effectiveness of the FINGER prevention program. <i>Alzheimer's and Dementia</i> , 2023, 19, 999-1008.	0.4	9
2	Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. <i>Lancet Public Health</i> , The, 2022, 7, e105-e125.	4.7	1,199
3	Cost of diagnosing and treating cognitive complaints: One-year cost-evaluation study in a patient cohort from a Slovenian memory clinic. <i>Zdravstveno Varstvo</i> , 2022, 61, 76-84.	0.6	1
4	Global and regional spending on dementia care from 2000–2019 and expected future health spending scenarios from 2020–2050: An economic modelling exercise. <i>EclinicalMedicine</i> , 2022, 45, 101337.	3.2	50
5	Changes in dementia diagnoses in Sweden during the COVID-19 pandemic. <i>BMC Geriatrics</i> , 2022, 22, 365.	1.1	10
6	What are the difficulties of implementing innovative pharmacy practice models in the care of patients with dementia?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 1-4.	0.7	1
7	A validation study of the CarerQol instrument in informal caregivers of people with dementia from eight European countries. <i>Quality of Life Research</i> , 2021, 30, 577-588.	1.5	11
8	Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. <i>Neurology</i> , 2021, 96, e2220-e2230.	1.5	75
9	A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1149-1159.	1.2	4
10	Response and Adherence of Nursing Home Residents to a Nutrition/Exercise Intervention. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1939-1945.e3.	1.2	7
11	Do caregiver profiles predict the use of dementia care services? Findings from the Actifcare study. <i>Aging and Mental Health</i> , 2020, 24, 272-279.	1.5	7
12	Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS. <i>International Psychogeriatrics</i> , 2020, 32, 267-277.	0.6	40
13	Is there equity in initial access to formal dementia care in Europe? The Andersen Model applied to the Actifcare cohort. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 45-52.	1.3	13
14	A validation study of the ICECAP-O in informal carers of people with dementia from eight European Countries. <i>Quality of Life Research</i> , 2020, 29, 237-251.	1.5	8
15	The art of simulation. <i>The Lancet Healthy Longevity</i> , 2020, 1, e2-e3.	2.0	1
16	A cost-consequence analysis of early detection of AD in the MOPEAD project – A project within the EU research agenda IML2. <i>Alzheimer's and Dementia</i> , 2020, 16, e042774.	0.4	0
17	Quantifying and Describing the Natural History and Costs of Alzheimer's Disease and Effects of Hypothetical Interventions. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 891-902.	1.2	22
18	Effect of Sit-to-Stand Exercises Combined With Protein-Rich Oral Supplementation in Older Persons: The Older Person's Exercise and Nutrition Study. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1229-1237.	1.2	16

#	ARTICLE	IF	CITATIONS
19	Time to invest in prevention and better care of behaviors and psychological symptoms associated with dementia. <i>International Psychogeriatrics</i> , 2020, 32, 567-572.	0.6	24
20	Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling framework. <i>Alzheimer's and Dementia</i> , 2019, 15, 1309-1321.	0.4	38
21	The MOPEAD project: Advancing patient engagement for the detection of "hidden" undiagnosed cases of Alzheimer's disease in the community. , 2019, 15, 828-839.		20
22	Classification tree model of the personal economic burden of dementia care by related factors of both people with dementia and caregivers in Japan: a cross-sectional online survey. <i>BMJ Open</i> , 2019, 9, e026733.	0.8	9
23	Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia. <i>European Journal of Health Economics</i> , 2019, 20, 343-355.	1.4	26
24	Resource use and its association to cognitive impairment, ADL functions, and behavior in residents of Swedish nursing homes: Results from the UÅAge program (SWENIS study). <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 130-136.	1.3	11
25	Challenges and recommendations for the health-economic evaluation of primary prevention programmes for dementia. <i>Aging and Mental Health</i> , 2019, 23, 53-59.	1.5	12
26	Costs of Care of Agitation Associated With Dementia in 8 European Countries: Results From the RightTimePlaceCare Study. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 95.e1-95.e10.	1.2	39
27	The End of the Beginning of the Alzheimer's Disease Nightmare: A Devil's Advocate's View. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S41-S46.	1.2	12
28	Apolipoprotein E genotypes and longevity across dementia disorders. <i>Alzheimer's and Dementia</i> , 2018, 14, 895-901.	0.4	8
29	Impact of Untimely Access to Formal Care on Costs and Quality of Life in Community Dwelling People with Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1165-1174.	1.2	9
30	Quality of Life, Care Resource Use, and Costs of Dementia in 8 European Countries in a Cross-Sectional Cohort of the Actifcare Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1027-1040.	1.2	30
31	A study protocol of Older Person's Exercise and Nutrition Study (OPEN) - a sit-to-stand activity combined with oral protein supplement " effects on physical function and independence: a cluster randomized clinical trial. <i>BMC Geriatrics</i> , 2018, 18, 138.	1.1	9
32	The personal cost of dementia care in Japan: A comparative analysis of residence types. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1243-1252.	1.3	9
33	Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 312-321.	0.4	34
34	Formal and informal care of community-living older people: A population-based study from the Swedish National study on Aging and Care. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 17-24.	1.5	29
35	What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 797-812.	1.2	23
36	Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017, 7, 87-100.	0.6	36

#	ARTICLE	IF	CITATIONS
37	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. <i>Neurobiology of Aging</i> , 2017, 59, 1-9.	1.5	84
38	Costs of dementia in the Czech Republic. <i>European Journal of Health Economics</i> , 2017, 18, 979-986.	1.4	21
39	The worldwide costs of dementia 2015 and comparisons with 2010. <i>Alzheimer's and Dementia</i> , 2017, 13, 1-7.	0.4	762
40	The economic burden of dementia in China, 1990-2030: implications for health policy. <i>Bulletin of the World Health Organization</i> , 2017, 95, 18-26.	1.5	138
41	Cohort Effects in the Prevalence and Survival of People with Dementia in a Rural Area in Northern Sweden. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 387-396.	1.2	32
42	The societal costs of dementia in Sweden 2012 - relevance and methodological challenges in valuing informal care. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 59.	3.0	35
43	The impact of dementia on drug costs in older people: results from the SNAC study. <i>BMC Neurology</i> , 2016, 16, 28.	0.8	6
44	Access to timely formal dementia care in Europe: protocol of the Actifcare (ACcess to Timely Formal) Trial. <i>BMJ Open</i> , 2016, 10, e008366.	0.9	36
45	The Umeå ageing and health research programme (U-Age): Exploring person-centred care and health-promoting living conditions for an ageing population. <i>Nordic Journal of Nursing Research</i> , 2016, 36, 168-174.	0.6	27
46	Cost of Dementia and Its Correlation With Dependence. <i>Journal of Aging and Health</i> , 2016, 28, 1448-1464.	0.9	34
47	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , 2016, 15, 455-532.	4.9	1,242
48	Horizontal and vertical targeting: a population-based comparison of public eldercare services in urban and rural areas of Sweden. <i>Aging Clinical and Experimental Research</i> , 2016, 28, 147-158.	1.4	4
49	F1-04-01: Care interventions practices through research on policy. <i>Alzheimer's and Dementia</i> , 2015, 11, P119-P119.		0
50	SveDem, the Swedish Dementia Registry - A Tool for Improving the Quality of Diagnostics, Treatment and Care of Dementia Patients in Clinical Practice. <i>PLoS ONE</i> , 2015, 10, e0116538.	1.1	124
51	Cerebrospinal fluid tau and amyloid- $\beta$ in patients with dementia. <i>Brain</i> , 2015, 138, 2716-2731.	3.7	152
52	Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. <i>Alzheimer's and Dementia</i> , 2015, 11, 1470-1479.	0.4	17
53	Determinants of societal costs in Alzheimer's disease: GERAS study baseline results. <i>Alzheimer's and Dementia</i> , 2015, 11, 933-945.	0.4	62
54	Long-term effects of Alzheimer's disease treatment. <i>Lancet Neurology</i> , 2015, 14, 1145-1146.	4.9	11

#	ARTICLE	IF	CITATIONS
55	Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2015, 11, 896-905.	0.4	19
56	Brain Health: A Primary Health Care Viewpoint. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 720-721.	1.2	16
57	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 455-461.	0.4	9
58	Horizontal and vertical target efficiency – a comparison between users and non-users of public long-term care in Sweden. <i>Ageing and Society</i> , 2014, 34, 700-719.	1.2	10
59	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. <i>Neurology</i> , 2014, 83, 1945-1953.	1.5	213
60	The Use and Costs of Formal Care in Newly Diagnosed Dementia: A Three-Year Prospective Follow-Up Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 381-388.	0.6	53
61	P3-419: COHORT EFFECTS IN THE PREVALENCE OF DEMENTIA AND SURVIVAL PATTERNS IN NORDANSTIG, A RURAL COHORT PROJECT (SNAC-N) IN NORTHERN SWEDEN. , 2014, 10, P783-P783.		0
62	The worldwide economic impact of dementia 2010. <i>Alzheimer's and Dementia</i> , 2013, 9, 1.	0.4	780
63	Application of Resource Utilization in Dementia (RUD) instrument in a global setting. <i>Alzheimer's and Dementia</i> , 2013, 9, 429.	0.4	128
64	The global prevalence of dementia: A systematic review and metaanalysis. <i>Alzheimer's and Dementia</i> , 2013, 9, 63.	0.4	3,654
65	A Quick Test of Cognitive Speed (AQT): Usefulness in dementia evaluations in primary care. <i>Scandinavian Journal of Primary Health Care</i> , 2013, 31, 13-19.	0.6	18
66	Costs of diagnosing dementia: results from SveDem, the Swedish Dementia Registry. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 1039-1044.	1.3	33
67	Mortality and Treatment Costs have a Great Impact on the Cost- Effectiveness of Disease Modifying Treatment in Alzheimer's Disease - A Simulation Study. <i>Current Alzheimer Research</i> , 2013, 10, 207-216.	0.7	42
68	The economic impact of galantamine vs placebo: An analysis based on functional capacity in a Swedish cohort study. <i>Journal of Medical Economics</i> , 2012, 15, 1019-1024.	1.0	2
69	Dementia Diagnosis Differs in Men and Women and Depends on Age and Dementia Severity: Data from SveDem, the Swedish Dementia Quality Registry. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 90-95.	0.7	37
70	Net costs of dementia in Sweden – An Incidence Based 10 Year Simulation Study. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 1112-1117.	1.3	15
71	Predictors of costs of care in Alzheimer's disease: A multinational sample of 1222 patients. <i>Alzheimer's and Dementia</i> , 2011, 7, 318-327.	0.4	117
72	Cost-Effectiveness of a Health Intervention Program with Risk Reductions for Getting Demented: Results of a Markov Model in a Swedish/Finnish Setting. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 735-744.	1.2	27

#	ARTICLE	IF	CITATIONS
73	Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2011, 23, 73-85.	0.6	92
74	Willingness to pay for reductions in care need: estimating the value of informal care in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 622-632.	1.3	28
75	Caregiver Time and Cost of Home Care for Alzheimer's Disease: A Clinic-based Observational Study in Beijing, China. <i>Ageing International</i> , 2010, 35, 153-165.	0.6	20
76	The cost of diagnosing dementia in a community setting. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 476-482.	1.3	20
77	The Art of Cost of Illness. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 617-619.	1.2	12
78	The worldwide societal costs of dementia: Estimates for 2009. <i>Alzheimer's and Dementia</i> , 2010, 6, 98-103.	0.4	355
79	The Cost of Dementia in Europe. <i>Pharmacoeconomics</i> , 2009, 27, 391-403.	1.7	152
80	International price comparisons of Alzheimer's drugs: a way to close the affordability gap. <i>International Psychogeriatrics</i> , 2009, 21, 1116-1126.	0.6	21
81	Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. <i>Lancet Neurology</i> , The, 2008, 7, 812-826.	4.9	960
82	A Swedish programme for dementia diagnostics in primary healthcare. <i>Scandinavian Journal of Primary Health Care</i> , 2008, 26, 235-240.	0.6	18
83	Cost-effectiveness of treatments for Alzheimer's dementia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 83-90.	0.7	4
84	Clinical and economic outcomes – friend or foe?. <i>International Psychogeriatrics</i> , 2007, 19, 497-507.	0.6	13
85	An estimate of the total worldwide societal costs of dementia in 2005. , 2007, 3, 81-91.		233
86	Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project—a population based study in Sweden. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 639-648.	1.3	46
87	Validity and reliability of assessments of time. <i>Archives of Gerontology and Geriatrics</i> , 2007, 44, 71-81.	1.4	95
88	Patient- and Proxy-Reported Utility in Alzheimer Disease Using the EuroQoL. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 49-55.	0.6	133
89	Determinants of costs of care for patients with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 449-459.	1.3	192
90	The Association of Inappropriate Drug Use with Hospitalisation and Mortality. <i>Drugs and Aging</i> , 2005, 22, 69-82.	1.3	242

#	ARTICLE	IF	CITATIONS
91	Impact of donepezil treatment for Alzheimer's disease on caregiver time. Current Medical Research and Opinion, 2004, 20, 1221-1225.	0.9	49
92	A longitudinal study integrating population, care and social services data. The Swedish National study on Aging and Care (SNAC). Aging Clinical and Experimental Research, 2004, 16, 158-168.	1.4	365
93	Cost Effectiveness of Cholinesterase Inhibitors in the Treatment of Alzheimer's Disease. Drugs and Aging, 2004, 21, 279-295.	1.3	39
94	Pharmacoeconomics of mild cognitive impairment. Acta Neurologica Scandinavica, 2003, 107, 94-99.	1.0	24
95	Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer's Disease. Pharmacoeconomics, 2003, 21, 327-340.	1.7	145
96	An Economic Evaluation of Donepezil in Mild to Moderate Alzheimer's Disease: Results of a 1-Year, Double-Blind, Randomized Trial. Dementia and Geriatric Cognitive Disorders, 2003, 15, 44-54.	0.7	93
97	The Magnitude of Dementia Occurrence in the World. Alzheimer Disease and Associated Disorders, 2003, 17, 63-67.	0.6	423
98	Societal Burden and Economics of Vascular Dementia: Preliminary Results From a Swedish-Population-Based Study. International Psychogeriatrics, 2003, 15, 251-256.	0.6	15
99	Costs of Dementia: A Review. , 2003, , 341-387.		2
100	Assessment of Health Economics in Alzheimer's Disease (AHEAD). Pharmacoeconomics, 2002, 20, 629-637.	1.7	39
101	Time spent on informal and formal care giving for persons with dementia in Sweden. Health Policy, 2002, 61, 255-268.	1.4	118
102	Costs of Dementia: A Review. , 2002, , 335-381.		5
103	Health Economical Aspects of Alzheimer Disease and its Treatment. Psychogeriatrics, 2001, 1, 189-193.	0.6	16
104	Severe dementia: a common condition entailing high costs at individual and societal levels. , 1999, 14, 911-914.		22
105	Costs of Mini Mental State Examination-Related Cognitive Impairment. Pharmacoeconomics, 1999, 16, 409-416.	1.7	65
106	The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: A Markov model. Clinical Therapeutics, 1999, 21, 1230-1240.	1.1	94
107	Costs of dementia and dementia care: a review. International Journal of Geriatric Psychiatry, 1997, 12, 841-856.	1.3	80
108	Costs of dementia and dementia care: a review. International Journal of Geriatric Psychiatry, 1997, 12, 841-856.	1.3	2

#	ARTICLE	IF	CITATIONS
109	Cost-Utility Analysis of Group Living in Dementia Care. International Journal of Technology Assessment in Health Care, 1995, 11, 49-65.	0.2	42
110	Patients With Dementia in Group Living: Experiences 4 Years After Admission. International Psychogeriatrics, 1995, 7, 123-127.	0.6	9
111	Cost-effectiveness analysis of day care for patients with dementia disorders. Health Economics (United Kingdom), 1994, 3, 395-404.	0.8	32
112	Predictive Validity of Factors Influencing the Institutionalization of Elderly People with Psycho-Geriatric Disorders. Scandinavian Journal of Primary Health Care, 1992, 10, 185-191.	0.6	27
113	Impact of Day Care on Dementia Patients's Costs, Well-being and Relatives' Views. Family Practice, 1990, 7, 279-287.	0.8	34
114	Benefits of Donepezil on Cognition, Function and Neuropsychiatric Symptoms in Patients with Mild and Moderate Alzheimer's Disease over One Year. , 0, , 725-738.		1